Cullinan Therapeutics (CGEM) Operating Leases (2022 - 2026)

Cullinan Therapeutics' Operating Leases history runs 5 years deep, the most recent figure standing at $1.7 million for Q1 2026.

• On a quarterly basis, Operating Leases rose 236.31% year-over-year to $1.7 million in Q1 2026; TTM through Mar 2026 was $1.7 million, a 236.31% increase from a year earlier, with the FY2025 full-year figure at $1.9 million, up 124.15% from the prior year.
• Operating Leases eased to $1.7 million in Q1 2026 per CGEM's latest filing, from $1.9 million in the prior quarter.
• Across five years, Operating Leases topped out at $4.0 million in Q3 2022 and bottomed at $125000.0 in Q2 2025.
• The 5-year median for Operating Leases is $1.7 million (2024), against an average of $1.8 million.
• Across the five-year window, Operating Leases jumped 358.72% in 2023 and plunged 91.77% in 2025, its largest moves.
• Year by year, Operating Leases stood at $3.6 million in 2022, then slumped by 40.11% to $2.2 million in 2023, then slumped by 60.51% to $849000.0 in 2024, then jumped by 124.15% to $1.9 million in 2025, then slipped by 12.87% to $1.7 million in 2026.
• Per Business Quant, the three latest CGEM Operating Leases figures stand at $1.7 million (Q1 2026), $1.9 million (Q4 2025), and $125000.0 (Q2 2025).